Distribution of fungal agents in the respiratory system of patients with underlying lung diseases; molecular identification and antifungal susceptibility profiles Authors: Parviz Hassanpour, Seyed Jamal Hashemi, Sanam Nami, Roshanak Daie Ghazvini, Behrouz Naghili Hokmabadi, Abbas Rahimi Foroushani, Kazem Ahmadikia, Zahra Ramezanalipour, Saeid Firouzi Abriz Published: 2024 ABSTRACT Background and Objectives:Airway fungal infection is a severe clinical problem, especially in patients with compromised immune functions. Here, we examined the distribution and antifungal susceptibility profiles of fungal agents isolated from respiratory tract of symptomatic patients hospitalized in pulmonary units.Materials and Methods:This descriptive cross-sectional study took place from 2023 to 2024, involving 360 patients. Bronchoalveolar lavage (BAL) or sputum specimens were collected and analyzed using mycological and molecular methods for this study. Antifungal susceptibility testing (AFST) was carried out using the broth micro dilution method.Results:Of a total of 360 respiratory specimens, 114 (31.6%) were positive. The male-to-female ratio was 63:51 (1.3%). Candida albicans and Aspergillus flavus were the most common yeast and mold species. Chronic obstructive pulmonary disease (COPD) had the highest rate of colonization with fungal agents (47/114, 41%). The isolates associated with COPD in this study included Aspergillus species (4/12, 3.5%), Candida species (41/96, 36%), and other fungal species (2/6, 1.5%). Coughing (87%) was the predominant symptom, and malignancy (52%) was the predominant comorbidity factor. The result of AFST for antifungal agents showed that 9 (22.5%) Candida isolates were resistant, and the highest rate of resistance was related to voriconazole agent (5/9, 55.5%). Resistance to antifungal agents was not observed among Aspergillus isolates.Conclusion:This study showed a significant relationship between the frequency of Aspergillus and Candida species in patients with underlying lung diseases. In addition, voriconazole was more effective than itraconazole, especially against Aspergillus flavus. INTRODUCTION Fungal lung infections have emerged as a worldwide healthcare problem in the last two decades, a significant proportion of which are community-acquired (1). Respiratory system infections occur following exposure to yeasts and molds implicated in lung pathologies. Clinical features, disease severity, and mortality rates vary among patients with underlying lung disease or individuals exhibiting symptoms such as cough, shortness of breath, chest pain, and bronchiectasis (2). Diagnosing fungal respiratory infections often relies on a combination of clinical, radiologic, and microbiological factors (3). The bronchoalveolar lavage (BAL) specimen represents a valuable tool for diagnosing fungal lung infections in high-risk patients, and sputum culture provides diagnosis in less than 50% of pneumonia patients (4, 5). Early and precise diagnosis of fungal lung infections is crucial for timely starting antifungal treatment and reducing the unnecessary use of toxic antifungal agents. Although traditional approaches such as direct microscopic examination, histopathological evaluation and cultivation are still the gold standard, of PCR-based diagnosis assays have been developed, and they can improve early diagnosis of fungal lung infections with the advantages of high sensitivity, the ability to establish diagnosis at the species level, and the capacity to detect genes that confer antifungal resistance. Several studies have indicated that most respiratory infections stem from the genera Aspergillus and Candida (6). To our knowledge, susceptibility assessments for fungi are not routinely performed in treating pulmonary infections. Therefore, clinicians must be familiar with clinical presentation, diagnostic methods, and treatment management. In this study, we investigated the distribution of fungal agents in the respiratory system among patients with underlying lung disease using molecular analysis and phylogenetic tools. Additionally, we examined the antifungal susceptibility profiles of isolated strains using the broth microdilution method. This study emphasized the microbiological and epidemiological aspects of the topic. MATERIALS AND METHODS Study design and dligibility criteria. This descriptive cross-sectional study was carried out from 2023 to 2024, involving 360 individuals previously diagnosed with underlying lung disease and hospitalized in different centers in Tabriz, Iran. This study was approved by the ethical committee of Tehran University of Medical Sciences (the number of Ethics Committee protocol: IR.TUMS.SPH.REC.1402.106). All subjects or their companions were provided with written informed consent before sample collection. Subsequently, all data were collected. Additionally, medical records, including information on underlying lung disease, comorbidity impact, clinical symptoms, radiographic signs, as well as demographic data such as age and sex, were captured and documented whenever available. The criteria for entering people into this study included patients who were previously diagnosed with an underlying lung disease (Chronic obstructive pulmonary disease) (COPD), asthma, bronchiectasis, pulmonary tuberculosis (TB), interstitial lung disease (ILD), and others, who were hospitalized. Exclusion from the study was applied to patients who had received systemic antifungal treatment within three days preceding sample collection. Specimens collection and mycological examination. Sputum specimens and BAL specimens were collected by Physicians and immediately sent to the laboratory of medical mycology at the School of Medicine in Tabriz, and microscopic and culture experiments were performed on the specimens in the shortest time possible. Before microscopic examination and performing culture cultivation, the sputum samples were diluted with sterile saline, BAL samples were centrifuged and the sediment of this sample was used for analysis. All sputum and BAL samples were examined using potassium hydroxide (KOH 10%) solution and examined under a microscope (Olympus. Germany) to detect presence or absence of the fungal agents. Culturing involved inoculating samples on Sabouraud dextrose agar (SDA) (Merck, Germany) supplemented with antibiotics (chloramphenicol) and Brain Heart Infusion (BHI) agar media (Merck, Germany), followed by incubation at 32°C for 72 hours (7). After colony growth, the isolates were identified by macroscopic appearance (hypha/yeast, Surface topography, texture, and pigment). Yeast isolates were identified based on mycological tests including production of chlamydoconidia in cornmeal agar (Becton, France) and colony color on chromogenic CHROM agar Candida medium (HiCrome™, France). Filamentous fungi were recognized using morphological characterization on Czapek Dox Agar (Sigma Aldrich, USA) and slide culture technique. Eventually, for molecular assays and antifungal susceptibility testing (AFST), we transferred pure colonies to eppendorf tubes containing sterile water and stored them at −18°C (8). Molecular identification of fungal isolates: Genomic DNA extraction. DNA was extracted from the mycelium of pure culture colonies using phenol-chloroform method (9), and the boiling method was applied for DNA extraction of the yeasts (10). DNA quality was checked via running 2–3 μL on an agarose gel (0.8%). In order to determine yeast, the primers were used for the amplification of the internal transcribed spacer (ITS) region (ITS 1, 5′ -TCC GTA GGT GAA CCT GCG G-3′; ITS 4, 5′ -TCC TCC GCT TAT TGA TAT G-3′) (8), and in order to determine Aspergillus, tubulin gene (benA), was amplified and sequenced using Bt2a (5′-GGT AAC CAA ATC GGT GCT GCT TTC-3′) and Bt2b (5′-ACC CTC AGT GTA GTG ACC CTT GGC-3′) (11). Polymerase chain reaction (PCR) and sequencing analysis. Polymerase chain reaction (PCR) amplification for each Aspergillus isolate was performed as described previously (8). Positive PCR products were sent for sequencing (Codon genetics group, Iran). The sequences were aligned using the Basic Local Alignment Tool Search (BLAST) to check their probable similarities with submitted fungal sequences on GeneBank. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). A PCR-RFLP method for identification Candida spp. was carried out according to the previously approved protocol introduced by Shokohi et al. (12). In this procedure we used MspI (HpaII) enzyme. Finally, Candida spp. were identified according to each electrophoretic band pattern and size. In-vitro antifungal susceptibility testing (AFST). The AFST was performed using broth micro dilution techniques according to Clinical and Laboratory Standards Institute guidelines (CLSI), M27-A3, S4 and M38-A2, M59 (13–15). In brief, the susceptibilities of the isolates to itraconazole (ITC) (Sigma-Aldrich, USA), voriconazole (VRC) (Sigma-Aldrich, USA), amphotericin B (AMB) (Sigma-Aldrich, USA), and caspofungin (CAS) (Sigma-Aldrich, USA), were assayed by the broth micro dilution method. Isolates were grown on potato dextrose agar (PDA) at 35°C up to 48–72 h to maximize conidial harvest, and the conidia were counted with a Neubauer chamber and adjusted to a concentration of 106 CFU/mL (13, 16). The micro dilution was performed with twofold dilutions of the drugs at concentrations ranging from 0.031 to 16 μg/mL. For Candida and Aspergillus isolates, the Minimum inhibitory concentration (MICs) endpoints for AMB, ITC, VRC and CAS were determined using a reading mirror as the lowest concentration of the drug at which it prevents any recognizable growth (100% inhibition) (8, 15). Minimum effective concentration (MECs) were determined for CAS in the Aspergillus isolates and they were only defined microscopically. At the lowest concentrations, the drug leads to the growth of small, rounded, compact hyphal forms as opposed to the long, unbranched hyphal clusters seen in the growth control. For quality control, strains including Aspergillus flavus ATCC®204304 and Candida parapsilosis ATCC®22019 were incorporated, relying on their defined MICs. Susceptibility assessments were conducted through duplicate measures in laboratories. We used the previously described Epidemiological cut-off values (ECVs) for each antifungal to detect the isolates within each species that might have acquired a mutational resistance mechanism to a given agent (17). Also for Aspergillus isolates, according to CLSI guideline we used terms wild-type (WT) and non-wild–type (NWT) instead of susceptible and resistant, respectively. We used AFST just for Candida and Aspergillus isolates. Statistical analysis. The collected data were analyzed in SPSS software (version 26, Statistical Product and Services Solutions, Inc, Chicago, IL, USA), and a p-value of ≤ 0.05 was considered statistically significant. We summarized the data using descriptive statistics, presenting continuous variables as median, interquartile range, and categorical variables as proportions or percentages. RESULTS Study population and clinical profile of patients. A total of 360 patient cases, hospitalized in different centers, 206 (57%) male and 154 (43%) female were recruited. The male to female odds-ratio was 206:154 (1.33%). Of this population, 114 (31.6%) were positive that the male-to-female ratio was 63 (55.2%) to 51 (44.8%). According to the age of the patients, 25 (7%) of the patients were less than 10 years old, 220 (61%) of the patients were between 11–49 years old, and 115 (32%) of the patients were over 50 years old. All patients were previously diagnosed with an underlying lung disease and hospitalized in different centers in Tabriz, Iran (Table 1). In this study, the average length of a patients’ hospital stay was 14 days and the length range was 1 to 45 days. In the pulmonary function tests conducted by a specialist doctor, most patients showed COPD (41%) and asthma (21%) followed by shortness of breath, hemoptysis, chest pain, and high fever (Fig. 1). In the review of radiological findings performed on patients on average one week after the onset of symptoms, the main findings were lobular infiltration and multifocal infiltration, and more specific symptoms, such as halo or air crescent symptoms, were not observed. The recorded data of patients’ files showed that diabetes mellitus (DM), cardiovascular disease (CVD), renal disease, malignancy, and autoimmune disease had comorbidity impacts in hospitalized patients. Demographic and clinical information of pulmonary patients is represented in Fig. 2. Frequency of underlying lung diseases in hospitalized patients (N %). COPD, Chronic obstructive pulmonary disease; ILD, interstitial lung disease; TB, tuberculosis Clinical symptoms and comorbidity impact hospitalized patients. (A) Frequency of clinical symptoms in hospitalized patients. (B) The recorded data of patients’ files showed that malignancy, diabetes mellitus (DM), cardiovascular disease (CVD), renal disease, malignancy, and autoimmune disease had comorbidity impacts in hospitalized patients. Table 1.Socio-demographic and clinical data of patients who participated in the study Variables Total 360 (100%) Colonization 114 (100%) p-Value Odds Ratio (OR) 95% confidence interval (95% CI) Gender Male206 (57%)63 (55%)0.86OR:1.57 Female154 (43%)51 (45%)95% CI: (1.52 to 1.62)Age groups (years) <1025 (6.9%)1 (0.8%)0.57OR:2.24 11–49221 (61%)65 (57%)95% CI: (2.18 to 2 .30) ≥50114 (32.1 %)49 (42.2%)Specimens Sputum76 (21%)26 (23%)0.00OR:1.23 Bronchoalveolar Lavage284 (79%)88 (77%)95% CI: (1.19 to 1.28) Socio-demographic and clinical data of patients who participated in the study Fungal agents and correlation with underlying lung diseases. The investigated samples were collected from patients by sputum 76 (21%) and BAL 284 (79%), and the results showed that 114 fungal species were isolated from 360 investigated patients, and the frequency of isolates was 31%. Among the study population, the specimen’s frequency according to gender was 41 (54.2%) sputum specimens and 164 (57.7%) BAL specimens were collected from males. Meanwhile, 35 (45.8%) sputum specimens and 120 (42.3%) BAL specimens were collected from females. Direct microscopic examination showed the presence of hyphae in 3 patients and budding yeast cells in 10 patients; these isolates also were isolated by culture. Finally, 114 isolates were observed by culture and microscopic examination. This result means that direct microscopic examination did not identify 101 out of 114 isolated fungi observed by culture (Table 2). The results showed Aspergillus spp. presence in 12 patients (including A. flavus in 6 patients, A. fumigatus in 2 patients, A. terreus in 1, A. tubingensis in 1, and A. niger in 2 patients) and Candida spp. presence in 96 (C. albicans, C. tropicalis, C. krusei, C. parapsilosis and C. glabrata being isolated from 56, 17, 9, 6 and 8 patients, respectively). Six patients with different underlying lung diseases showed growth of other fungal isolates. The distribution of the fungal isolates concerning the diagnostic groups is represented in Fig. 3. Out of 12 Aspergillus isolates, 4 (33.3%) were isolated from patients with COPD, 3 (25%) from asthmatic patients, 1 (8.3%) from ILD patients, 2 (17%) from patients with bronchiectasis, and 2 (17%) from pulmonary TB patients. Out of 96 candida isolates, 41 (43%) were isolated from patients with COPD, 19 (19.7%) from asthmatic patients, 7 (7.3%) from ILD, 11 (11.4%) from patients with bronchiectasis, and 18 (18.6%) from pulmonary TB patients. Also, Rhizopus genus was isolated from patients with COPD, Thrichosporon from sthmatic patients, Scedosporium from ILD patients, Geotrichum from patients with bronchiectasis, and Alternaria from pulmonary TB patients. The correlation between isolated fungi and underlying lung diseases is represented in Table 3. Distribution of the fungal isolates concerning the diagnostic groups (n=114). Table 2.Results of the direct examination and culture Positivity rates of the methods Direct examination (+) and culture (−) Direct examination and culture (+) Hyphae Budding yeast cells Total Mold Yeast Total Frequency of 360 patients310 13 1896114Percentage (%)0.832.7 3.6 526.631.6 Results of the direct examination and culture Table 3.Correlation between fungal isolates and underlying lung diseases. Underlying lung diseases COPD Asthma Bronchiectasis ILD TB Other Isolated Aspergillus spp. n=12 (10.5%)4 (3.5%)3 (2.5%)1 (0.8%)2 (1.7%)2 (1.7%)0Isolated Candida spp. n=96 (84%)41 (36%)19 (16.7%)7 (6.2%)11 (9.3%) 18 (15.6%)0Isolated other fungal. n=6 (5.5%)2 (1.5%)2 (1.8%)002 (1.7%)0Total=114 (100%)47 (41%)24 (21%)8 (7%)13 (11%)22 (19%)0COPD, Chronic obstructive pulmonary disease; ILD, interstitial lung disease; TB, tuberculosis Correlation between fungal isolates and underlying lung diseases. COPD, Chronic obstructive pulmonary disease; ILD, interstitial lung disease; TB, tuberculosis Yeast identification based on the RFLP-PCR method. Utilizing a PCR–RFLP method, we identified medically significant Candida species using the universal primers ITS1 and ITS4 to amplify the ITS1 and ITS2 region and 5.8S in the rDNA gene. In the current study, the size of PCR Amplicon for C. albicans, C. tropicalis, C. krusei, C. parapsilosis, and C. glabrata were 537, 526, 510, 530, and 881 bp, respectively. Also, the size of MspI -RFLP fragments for C. albicans, C. tropicalis, C. krusei, C. parapsilosis, and C. glabrata were 239–298, 186–340, 250–260, 530 and 320–561 bp, respectively. The results showed that all Candida spp. detected via microbiological methods were confirmed by the RFLP-PCR assay (Fig. 4). Agarose gel electrophoresis of restriction digestion by the MspI enzyme of Candida strains in PCR-RFLP. lane 1, C. tropicalis; lane 2, C. parapsilosis; lane 3, C. glabrata; lane 4, C. krusei; lane 5, C. albicanse; M lane is 100 bp DNA markers, BP; Base pair, C lane is control negative. Mold identification based on PCR and sequencing reference method. In this investigation, fragments of the tubulin gene (benA) were amplified and sequenced using Bt2a and Bt2b primers for the identification of Aspergillus spp. 11 of 12 (91.6%) Aspergillus spp. that were detected via microbiological methods were confirmed by using the primers Bt2a and Bt2b, and 1 (8.4%) isolate were negative. The negative results may be attributed to the isolated species not being genetically the same so that it can be detected by Bt2a and Bt2b, or a mutation had occurred with the isolated species and changed the nucleotide sequence which was not associated with the mentioned primer. Isolated Aspergillus strains produced a PCR product of the tubulin gene with sizes ranging from 550 to 600 bp. In this study, Rhizopus, Thrichosporon, Scedosporium, Geotrichum and Alternaria were identified according to mycological method. Antifungal susceptibility testing (AFST). The ranges MIC/MEC, ECVs, and the distribution of MICs/MECs of four antifungal agents against the 40 candida isolates and 12 Aspergillus isolates are presented in Tables 4 and 5. Due to the pharmaceutical limitations of this project, drug sensitivity was conducted for 40 samples out of 96 Candida species and randomly selected for 12 /56 C. albicans samples and 11/17 C. tropicalis samples. In the present study, the susceptibility/resistance of the strains to each antifungal was evaluated according to the breakpoints and ECVs defined by CLSI and/or several researchers. The result of AFST for antifungal agents showed that (9/40, 22.5%) Candida isolates were resistant, and the highest rate of resistance was related to VRC agent (5/9, 55.5%). Resistance to antifungal agents was not observed among Aspergillus isolates which indicated that all isolates were within the WT. In this study, MIC50 and MIC90 were determined for numbers above 10 isolates. For each drug species pair, the MIC50 values differed in candida isolates, indicating that in all cases the MIC50 obtained by inspection reasonably reflected the central tendency of the antifungal susceptibility of the population. Table 4.Antifungal susceptibility pattern of antifungal agents against the Candida isolates Isolates No. of isolates with respective MICs (μg/ml) MIC profile (μg/ml) ECV profile Susceptibility profile Antifungal 0.031 0.062 0.125 0.25 0.5 1 2 4 8 >16 MIC range MIC50 MIC90 GM ECV ≤ECV >ECV S SDD R C. albicans (12/56)AMB2-11611--0.031–20.50.51.072120 * * * VRC7-12--1--10.031–160.0310.253.70.0675822ITC9---11--1-0.031–80.03112.42111912CAS8112------0.031–0.250.0310.250.230.251201200C. krusei (9)AMB21-1-211-10.031–161ND3.4272 * * * VRC2-41---1-10.031–160.25ND4.10.572702ITC42--1-1-10.031–160.125ND3.7272702CAS81--------0.031–0.620.031ND0.150.590900C. tropicalis (11/17)AMB4-1231----0.031–10.0310.50.672110 * * * VRC5-131----10.031–160.0310.253.50.1256641ITC7-31------0.031–0.250.0310.120.02821101100CAS821-------0.031–0.120.0310.0620.160.51101100C. glabrata (8)AMB3-12-11---0.031–20.031ND0.74280 * * * VRC52-1------0.031–0.250.031ND0.250.2580 * * * ITC5-1-2-----0.031–0.50.031ND0.42280800CAS52-1------0.031–0.250.031ND0.170.580710MIC: Minimum inhibitory concentration; GM: Geometric Mean; AMB: Amphotericin B; ITC: itraconazole; VRC: voriconazole; CAS: caspofungin; S: susceptible; SDD: susceptible-dependent-dose; R: resistant; ECV: epidemiologic cutoff values, ND: not determined;*Breakpoints not provided by CLSI document M27-S4. Antifungal susceptibility pattern of antifungal agents against the Candida isolates MIC: Minimum inhibitory concentration; GM: Geometric Mean; AMB: Amphotericin B; ITC: itraconazole; VRC: voriconazole; CAS: caspofungin; S: susceptible; SDD: susceptible-dependent-dose; R: resistant; ECV: epidemiologic cutoff values, ND: not determined; Breakpoints not provided by CLSI document M27-S4. Table 5.Antifungal susceptibility pattern of antifungal agents against the Aspergillus isolates. Isolates No.of isolates with respective MICs/MECs (μg/ml) MIC profile (μg/ml) ECV profile Susceptibility profile Antifungal 0.031 0.062 0.125 0.25 0.5 1 2 4 8 >16 MIC range GM ECV ≤ECV >ECV WT NWT A. flavus (6)AMB VRC1-1-1-12--0.03–81.643360ITC21-12-----0.03–0.50.3413360*CAS12--3-----0.03–0.50.5316060AMB231-------0.03–0.120.12NANANA60A. fumigatus (2)VRC--1--1----0.012–10.5622020ITC1---1-----0.03–0.50.2612020*CAS1---1-----0.2–0.50.2612020AMB11--------0.03–0.620.04NANANA20A. section nigri (3)VRC1----2----0.03–11.0123030ITC---12-----0.2–0.50.6223030*CAS----12----0.–11.2523030AMB111-------0.03–0.120.07NANANA30A.terreus (1)VRC-------1--4441010ITC-----1----1111010*CAS----1-----0.50.511010-1--------0.060.06NANANA10MIC: Minimum inhibitory concentration; MEC: Minimum effective concentration; GM: Geometric Mean; AMB: Amphotericin B; ITC: itraconazole; VRC: voriconazole; CAS: caspo-fungin; WT: wild-type; ECV: epidemiologic cutoff values, NA: not applicable;*for caspofungin MEC Range determined. (μg/ml) Antifungal susceptibility pattern of antifungal agents against the Aspergillus isolates. MIC: Minimum inhibitory concentration; MEC: Minimum effective concentration; GM: Geometric Mean; AMB: Amphotericin B; ITC: itraconazole; VRC: voriconazole; CAS: caspo-fungin; WT: wild-type; ECV: epidemiologic cutoff values, NA: not applicable; for caspofungin MEC Range determined. (μg/ml) DISCUSSION The present study was conducted in Tabriz -Northwest Iran, focusing on patients admitted to different hospitals in Tabriz city with underlying lung disease. This study represents the first attempt to isolate fungal species, examine their molecular characteristics, and assess them in vitro susceptibility to four antifungal agents. Among 360 patient samples, 114 fungal isolates (31.6%) were identified. This prevalence was consistent with studies by Rafat et al. from Gilan, Iran, and Akhtar et al. from Bhagalpur, India, who reported similar findings (18, 19). However, a study by Ahmed et al. in Egypt showed a notably higher prevalence (66.6%), which may reflect the broader spectrum of underlying diseases in their study population (6). In our study, as in the findings of Rafat et al. (18), in positive cases, the male-to-female ratio was 63 to 51, and there was no significant difference in the prevalence of fungal elements isolated from symptomatic patients hospitalized in pulmonary units between the genders. Similar exposure to pollution sources due to equal socio demographic conditions, occupations, and societal roles may account for the observed similarity between the two gender groups. In our study, the predominant age group among hospitalized patients ranged from 11 to 49 years, yet the highest occurrence of fungal isolates was noted in individuals aged 45 to 75 years. The results of this study are similar to the findings of other studies from different countries (20, 21). This finding suggests that fungal colonization rates likely increase with age and the presence of underlying conditions, such as DM. Direct microscopic examination, used to detect hyphal forms or budding yeast cells in clinical specimens, is a rapid and cost-effective diagnostic method (22). Our study showed that microscopic examination sensitivity was 11.4% in respiratory samples. This technique showed sensitivity only for 13 (11.4%) in respiratory samples, meaning it failed to detect 101 (88.6%) of the fungal isolates identified via culture. These findings align with studies by Moqled et al. (23) in Saudi Arabia, as well as Pagham et al. (24) from France, and and Agossou et al.(25) from France. In contrast, Njunda et al. (26) reported a much higher microscopic sensitivity of 90%. Additionally, Khodavaisy et al. showed negative microscopy results in patients with invasive pulmonary aspergillosis (27). While direct microscopic examination is less sensitive than culture, a negative result does not exclude fungal infection. Qualified mycological microscopes can enhance the sensitivity of microscopic examinations. The expertise of a mycologist is also crucial for accurate interpretation, for instance, in examining sputum samples, where hyphae are often visible alongside eosinophils and Charcot-Leyden crystals (22, 28). In our study, Candida albicans was the most predominant fungal isolate in patients with underlying lung diseases, accounting for 49% (56 cases). This finding aligns with previous studies by Rafat et al. (18) and Spahr et al. (29) which also identified C. albicans as the leading cause of pulmonary fungal infections. Globally, A. flavus is regarded as the second most prevalent Aspergillus species in medical laboratories and hospitals, following A. fumigatus. However, unlike other regions, epidemiological studies in Iran have shown that A. flavus is the most common causative species of aspergillosis (30). The climatic and environmental conditions of the region and the availability of conditions for growth have been the most favoring factors in the abundance of A. flavus agents in Iran (31, 32). In the present study, 6 (50%) of the 12 clinical Aspergillus isolates were identified as A. flavus, consistent with findings from previous researches. Several studies have examined the relationship between fungal infections and underlying lung diseases in hospitalized patients (33, 34). COPD, a prevalent inflammatory lung condition often linked to tobacco smoking, is one of the most significant risk factors. It is estimated that this disease can become the third cause of death in the future (33, 35). In our study, 47 (41%) COPD patients exhibited the highest rates of fungal colonization, with Aspergillus spp., Candida spp., and other fungal species isolated in 4 (3.5%), 41 (36%), and 2 (1.5%) cases, respectively. This observation is consistent with previous research, which identified COPD as a significant predisposing factor for colonization and infection by Aspergillus spp. (23, 33). Guinea et al. reported that 1.63% of COPD patients harbored Aspergillus spp. in their lower respiratory tract samples, with 22.1% showing probable IPA (36). Also, we observed that Candida colonization occurred in 41 patients (36%) with severe complications during the stable phase of COPD, which may be associated with worse clinical outcomes, particularly in critically ill patients. Delisle et al. (37) demonstrated an association between independent C. albicans colonization and prolonged hospital stays in ICU patients who met the clinical criteria for suspected ventilator-associated pneumonia (VAP). However, since Candida species can naturally be part of the respiratory system’s normal flora, it is crucial for physicians to carefully evaluate clinical findings to confirm whether the Candida isolate is indeed associated with a lung infection. Another objective of this research was to investigate the drug sensitivity of the isolates to AMB, ITC, VRC, and CAS. Treatment of fungal infections with an antifungal agent depends on the patient’s clinical condition, and these drugs can also be used as prophylaxis in high-risk patients (33). Based on the CLSI interpretive criteria for the most predominant yeast isolates, (31/40, 77.5%) of Candida spp. were susceptible to AMB, ITC, VRC, and CAS, while resistance was observed in 9 out of 40 isolates (25.5%), predominantly to VRC (55.5%) (38–40). Aspergillus flavus isolates (50%) exhibited MICs ≤ 4 μg/ml to AMB, and besides this, all Aspergillus isolates were WT or susceptible to AMB, ITC, VRC, and CAS, providing promising therapeutic options for treating mold infections. Triazole resistance, particularly in A. fumigatus, is a growing concern in clinical settings (41). Unlike some studies that have reported triazole-resistant Aspergillus isolates, our findings showed no such resistance (42). A key aspect in performing antifungal susceptibility tests is the clinical relevance of in vitro MICs. The correlation of increased MICs with molecular resistance to triazole antifungals and treatment failure has been recognized, specifically for Aspergillus spp. (2). ITC remains a preferred treatment for chronic pulmonary aspergillosis, while VRC is first-line for invasive aspergillosis (IA). Recently introduced triazoles like isavuconazole and posaconazole offer additional treatment options for IA and prophylaxis in high-risk patients, such as acute myeloid leukemia (43), but their availability in resource-limited settings remains challenging. We utilized a PCR-RFLP method to identify medically significant Candida species. Our findings were consistent with those of other published studies (44, 45), which also reported similar results when employing CHROMagar and PCR-RFLP methods to detect various Candida species. However, Shokohi et al.(12) and Hassanpour et al. (8) found that CHROMagar could be unreliable due to color interpretation issues, suggesting the need for standardized Candida strains to minimize diagnostic errors. Additionally, the expertise of a mycologist during fungal identification is crucial. Lastly, we applied PCR and sequencing reference methods to identify Aspergillus spp. In this method, the identification marker for Aspergillus spp. was the beta-tubulin gene. In our study, amplification with the beta-tubulin gene revealed that all isolates of Aspergillus spp. were positive and had amplicon sizes of 550–600 bp. These results were similar to those obtained in previous studies (11, 46, 47). In other research, beta-tubulin gene amplicon sizes ranged from 432 to 550 bp for Aspergillus, Penicillium, and other fungal species (48). While the ITS region serves as a universal primer for fungi, its utility in identifying most fungi to the species level is limited due to their low variability and slow evolution. Reports have shown that beta-tubulin genes exhibit more variability than the ITS region. Therefore, it has been suggested to utilize alternative molecular markers, such as calmodulin (CMD) and RNA Polymerase II Second Largest Subunit (RPB2), to enhance the accurate identification of fungal species and facilitate phylogenetic analysis. CONCLUSION The most important finding of this study was the isolation of 114 fungal isolates from 360 patients through direct examination and culture. Diabetes, transplantation, and malignancies were paramount risk factors in hospitalized patients with underlying pulmonary disease. C. albicans and A. flavus were the most common yeast and mold species responsible for pulmonary fungal colonization and/or infection among patients. In addition, antifungal VRC was more active than ITC, especially against A. flavus.